The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort
MURDOCK COPD Observational Study: The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort
Sponsor: Boehringer Ingelheim
Terminated
Sponsor Decision to Stop Recruitment
Other terminated trials from Boehringer Ingelheim
Other Chronic Bronchitis trials with similar outcome
This observational or N/A phase trial investigates Chronic Bronchitis and Chronic Obstructive Pulmonary Disease (COPD) and is currently terminated or withdrawn. Boehringer Ingelheim leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Nov 2019 — Jan 2021 [monthly]
Terminated
-
Jul 2018 — Nov 2019 [monthly]
Terminated
Status: Suspended → Terminated
▶ Show 5 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Suspended
-
May 2018 — Jun 2018 [monthly]
Suspended
Status: Recruiting → Suspended
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
May 2017 — Apr 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — May 2017 [monthly]
Not Yet Recruiting NA
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Duke University
For direct contact, visit the study record on ClinicalTrials.gov .